Valeant Agrees to Buy Egypt Drugmaker Amoun for $800 Million

Valeant Pharmaceuticals International Inc. agreed to buy Egyptian drugmaker Amoun Pharmaceutical Co. for $800 million, continuing its torrid pace of dealmaking by expanding further into emerging markets.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.